清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Assessing the Benefits and Risks of Amantadine for Irritability and Aggression after Traumatic Brain Injury

金刚烷胺 易怒 安慰剂 不利影响 医学 随机对照试验 心理学 需要伤害的数量 心理干预 精神科 需要治疗的数量 内科学 药理学 替代医学 病理 焦虑
作者
Flora M. Hammond,Ross Zafonte,Mark Sherer,Kathleen Bell,Jennifer Bogner,James F. Malec,Qing Tang,Jeong Hoon Jang
出处
期刊:Archives of Physical Medicine and Rehabilitation [Elsevier BV]
卷期号:102 (10): e5-e5
标识
DOI:10.1016/j.apmr.2021.07.402
摘要

Research Objectives To explore the benefits versus harms of amantadine in the treatment of irritability and aggression. Design Parallel-group, randomized, double-blind, placebo-controlled trial of amantadine versus placebo. Setting Outpatient. Participants 168 individuals with chronic TBI and irritability (amantadine n=82 versus placebo n=86). Interventions Amantadine 100 mg or placebo equivalent two times daily. Main Outcome Measures Number-Needed-To-Treat (NNT) and Number-Needed-to-Harm (NNH). NNT was calculated using number of individuals with improvement as indicated by Clinical Global Impressions – Global Improvement scale. NNH was calculated using 3 definitions of adverse outcome: number of participants with GI indicating worsening, number of participants with serious adverse events, and number of participants with adverse events. Results Based on clinician ratings, for every 6 patients treated with amantadine, 1 patient more than placebo would be expected to improve. More participants in the placebo group worsened than in the amantadine group. For every 27 patients treated, 1 more than the placebo would be expected to experience serious adverse events. More participants in the placebo group experienced adverse events of any severity than in the amantadine group. Conclusions Clinician ratings suggest moderate benefit with low risk to appropriately selected patients. Thus, amantadine should be considered a treatment option for the experienced brain injury clinician. These data may support treatment decisions when a pharmaceutical agent is being considered to control irritability/aggression. Author(s) Disclosures Dr. Hammond serves on the Avanir Scientific Advisory Committee. To explore the benefits versus harms of amantadine in the treatment of irritability and aggression. Parallel-group, randomized, double-blind, placebo-controlled trial of amantadine versus placebo. Outpatient. 168 individuals with chronic TBI and irritability (amantadine n=82 versus placebo n=86). Amantadine 100 mg or placebo equivalent two times daily. Number-Needed-To-Treat (NNT) and Number-Needed-to-Harm (NNH). NNT was calculated using number of individuals with improvement as indicated by Clinical Global Impressions – Global Improvement scale. NNH was calculated using 3 definitions of adverse outcome: number of participants with GI indicating worsening, number of participants with serious adverse events, and number of participants with adverse events. Based on clinician ratings, for every 6 patients treated with amantadine, 1 patient more than placebo would be expected to improve. More participants in the placebo group worsened than in the amantadine group. For every 27 patients treated, 1 more than the placebo would be expected to experience serious adverse events. More participants in the placebo group experienced adverse events of any severity than in the amantadine group. Clinician ratings suggest moderate benefit with low risk to appropriately selected patients. Thus, amantadine should be considered a treatment option for the experienced brain injury clinician. These data may support treatment decisions when a pharmaceutical agent is being considered to control irritability/aggression.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Maestro_S的应助被博修采纳,获得100
5秒前
魔幻荧完成签到,获得积分10
5秒前
张博完成签到 ,获得积分10
6秒前
LYH完成签到,获得积分10
12秒前
J_Xu完成签到 ,获得积分10
13秒前
七叶花开完成签到,获得积分10
13秒前
SunJay完成签到 ,获得积分10
14秒前
复杂以旋完成签到,获得积分10
22秒前
心无杂念完成签到 ,获得积分10
23秒前
Shicheng发布了新的文献求助10
24秒前
忧虑的静柏完成签到 ,获得积分10
27秒前
果酱完成签到,获得积分10
32秒前
科研通AI6.3的应助被leapper采纳,获得10
37秒前
如意2023完成签到 ,获得积分10
40秒前
阿晖完成签到,获得积分10
41秒前
鲜艳的念寒完成签到,获得积分10
41秒前
领导范儿的应助被菲菲采纳,获得10
45秒前
Zoe完成签到,获得积分0
51秒前
52秒前
彩色的可冥完成签到,获得积分10
52秒前
奔跑的应助被cc采纳,获得10
53秒前
程志强完成签到 ,获得积分10
53秒前
樂楽完成签到,获得积分10
55秒前
小孟小孟完成签到 ,获得积分10
59秒前
噜噜晓完成签到 ,获得积分10
1分钟前
xiepeijuan的应助被lili采纳,获得10
1分钟前
1分钟前
免疫小白完成签到 ,获得积分10
1分钟前
leapper发布了新的文献求助10
1分钟前
绵绵冰完成签到 ,获得积分10
1分钟前
1分钟前
开放的花卷完成签到 ,获得积分10
1分钟前
菲菲发布了新的文献求助10
1分钟前
龙行天下完成签到 ,获得积分10
1分钟前
大大完成签到 ,获得积分10
1分钟前
狞风妖完成签到 ,获得积分10
1分钟前
菲菲完成签到,获得积分10
1分钟前
悄然飘去完成签到 ,获得积分10
1分钟前
复杂妙海完成签到,获得积分10
1分钟前
轩辕十四完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173230
求助须知:如何正确求助?哪些是违规求助? 9565593
关于积分的说明 21780536
捐赠科研通 7767429
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555764
邀请新用户注册赠送积分活动 2476697